Diabetes

Diabetes

Diabetes related mortality is currently estimated at 6.7 million per year. According to the Diabetes Atlas 2021, released by IDF, there are ~537 million patients suffering from Diabetes (Type 1 and Type 2). The numbers are set to rise by 46% over the next 25 years. This rise is numbers is largely estimated to come from the global south. We are located in India, which is deemed the world’s capital of diabetes.

There are several opportunities that exist within the entire insulin treatment space and supply chain.

The first set of problems/opportunities for improvement include patient inconvenience, delayed initiation of insulin therapy and non-physiological delivery of insulin. All of these problems can be addressed by an effective oral insulin.

Additionally, insulin requires cold chain maintenance during manufacturing, storage and transportation. This increases the cost significantly and limits the accessibility of this vital drug. These challenges can be addressed by a thermostable insulin.

There are several opportunities that exist within the entire insulin treatment space and supply chain.

The first set of problems/opportunities for improvement include patient inconvenience, delayed initiation of insulin therapy and non-physiological delivery of insulin. All of these problems can be addressed by an effective oral insulin.

Additionally, insulin requires cold chain maintenance during manufacturing, storage and transportation. This increases the cost significantly and limits the accessibility of this vital drug. These challenges can be addressed by a thermostable insulin.

Intensive insulin therapy causes linear weight gain, which consequently increases insulin resistance, thereby leading to higher requirement of insulin, creating a vicious circle. WEIGHT REDUCING INSULIN will be a boon for inuslin users worldwide. Combining insulin and GLP-1-like activity within the same molecule could lead to the creation of a weight-reducing insulin.

Our Solutions

Oral Insulin

An viable oral insulin has been century old quest in insulin research due to several physiological and patient-level advantages. We are using rational in silico design to overcome the massive challenges related to bioavailability, dosage requirements, safety and half-life with novel insulins that are a mere 60-70% identical to human insulin.

Thermostable Insulin

Insulin and incretin duals could represent the next generation in Diabetes treatment. Currently, there are no known single molecule agonists of both insulin and incretin receptors. The major challenge is sequence divergence between the endogenous peptides. We are addressing through our innovative multi-targeting workflow.

Insulin GLP-1 Dual agonist

Currently, there are no reported peptides that are able to activate both the insulin and incretin pathways. Creating such a molecule represents a major challenge as they bind to completely unrelated targets. We are designing such a molecule using our innovative insulin engineering strategy and a breakthrough would open up an entirely new space for diabetes management.